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Abstract: In vitro primary screening for identifying bioactive compounds (inhibitors, activators 
or pharmacological chaperones) against a protein target results in the discovery of lead com-
pounds that must be tested in cell-based efficacy secondary screenings. Very often lead com-
pounds do not succeed because of an apparent low potency in cell assays, despite an excellent 
performance in primary screening. Primary and secondary screenings differ significantly accord-
ing to the conditions and challenges the compounds must overcome in order to interact with their 
intended target. Cellular internalization and intracellular metabolism are some of the difficulties 
the compounds must confront and different strategies can be envisaged for minimizing that prob-
lem. Using a novel screening procedure we have identified 15 compounds inhibiting the hepatitis 
C NS3 protease in an allosteric fashion. After characterizing biophysically the interaction 
with the target, some of the compounds were not able to inhibit viral replication in cell assays. 
In order to overcome this obstacle and potentially improve cellular internalization three of these 
compounds were complexed with γ-cyclodextrin. Two of them showed a five- and 16-fold 
activity increase, compared to their activity when delivered as free compounds in solution (while 
γ-cyclodextrin did not show antiviral activity by itself ). The most remarkable result came from 
a third compound that showed no antiviral activity in cell assays when delivered free in solu-
tion, but its γ-cyclodextrin complex exhibited a 50% effective concentration of 5 µM. Thus, the 
antiviral activity of these compounds can be significantly improved, even completely rescued, 
using γ-cyclodextrin as carrier molecule.
Keywords: primary and secondary screenings, drug activity, antiviral compounds, cyclodextrins, 
vehiculization, drug delivery, hepatitis C, NS3 protease, virus replicon system
Introduction
There is a permanent need for identifying new specific bioactive compounds. Regardless 
of their effect (inhibitors or activators), they must interact with a biomolecular target 
at a certain location within a given organism. High-throughput screening procedures 
allow for acceleration of the identification of lead compounds as potential candidates 
for drug development.1,2 Although high-throughput screening for identifying bioactive 
molecules can be performed by implementing activity assays at different levels and 
contexts of biological complexity (molecular target, cell, organism), in vitro primary 
screening is often based on probing the interaction of large collections of compounds 
with the isolated, purified biomolecular target. At this stage, biophysical studies are 
instrumental for confirming and providing direct evidence for the interaction of the 
selected compounds with the molecular target. Identified lead compounds are then 
assessed in cell-based activity assays as part of secondary screenings (regarding eg, 
activity, toxicity, side-effects etc). Very often lead compounds do not succeed and are 
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discarded as false positives, because of an apparent low activ-
ity in cell-based assays, despite an excellent performance 
in primary screenings. However, primary and secondary 
screenings differ significantly according to the experimental 
conditions and the challenges the compounds must overcome 
in order to interact with their intended target at the appropriate 
intracellular location. Among others, cellular internalization 
and intracellular metabolism are some of the difficulties the 
compounds must confront in cell-based assays.
There are two main approaches to rescue the bioactivity 
level observed in primary screenings: 1) structural-functional 
modifications can be introduced in the compound in order 
to improve membrane transport or reducing cellular meta-
bolic degradation, yet maintaining the bioactivity level; 
2) a suitable non-toxic molecular carrier able to interact 
with the compound can be employed for storing, protecting 
and releasing the compound at the required intracellular 
location. Of course, if cellular metabolic degradation is the 
main cause for the failure of the lead compound, combination 
therapy with a second drug interfering with CYP-dependent 
metabolism can boost the pharmacodynamic profile of certain 
drugs (eg, pharmacological enhancement of the HIV-1 pro-
tease inhibitors by adding a second antiretroviral, usually 
ritonavir, at a concentration lower than that associated with 
antiretroviral activity).
Hepatitis C infection is a worldwide health problem of 
epidemic proportions affecting about 200 million people 
in the world.3,4 Recently, two NS3-4A protease inhibi-
tors, telaprevir and boceprevir, were approved, adding to 
the traditional combination therapy based on IFN-α and 
ribavirin. Despite their remarkable antiviral potency, drug 
resistance may develop at early stages during clinical 
therapy; therefore, potential long-term efficacy problems 
related to drug-resistance associated complications and viral 
breakthrough can be foreseen.5 The current triple therapy 
approach (pegylated IFN-α/ribavirin plus one of the pro-
tease inhibitors) represents a considerable improvement in 
comparison with the previous dual therapy.6–8 However, the 
efficacy of triple therapy still has some limitations in specific 
groups of patients; in particular, more than 85% of cirrhotic 
patients who are null-responders to the traditional therapy 
would not achieve sustained virologic response rates with 
the triple therapy.9 More recently, new specific direct-acting 
antivirals have been approved: sofosbuvir (against NS5B 
polymerase)10 and simeprevir (against NS3 protease).11 
In addition, IFN-free regimens are being developed and 
tested with promising results, thus, overcoming the severe 
side-effects and low patient adherence associated with IFN 
treatment.12 Nevertheless, new antivirals with high efficacy 
and high barrier to resistance development are needed.
Recently, an alternative, physiologically relevant confor-
mational state for NS3 protease has been described and the 
complex conformational landscape of the NS3 protease has 
been exploited for identifying new allosteric inhibitors.13,14 
Considering this alternative conformational state as a new drug 
target, chemical compounds binding to it will stabilize and trap 
the protein into that inactive partially-folded state and, there-
fore, will block the viral life cycle. This new allo steric mecha-
nism is the basis for a novel screening strategy for identifying 
potential antivirals that has been recently developed.15 Using 
this technique, 15 compounds were identified and all of them 
exhibited good in vitro activity. After the evaluation of their 
activity and cytotoxicity in cell assays, eight of them showed 
promising characteristics: low molecular weight, moderate-to-
high potency (from micromolar to nanomolar 50% effective 
concentration [EC50]) and moderate-to-low cytotoxicity.15 
However, three of these compounds exhibited low activity in 
cell assays, which could be related to their incapability to enter 
into the cells. After exploring different strategies to improve 
cell internalization for these compounds, we have assessed 
cyclodextrins (CDs) as molecular carriers.
The chemical structure of CDs, cyclic oligosaccharides 
composed of α-1,4-glycosidic-linked glycosyl residues, pro-
vides them structural and physico-chemical properties that 
allow their use as molecular carriers.16–21 In their hydropho-
bic cavity a wide range of compounds ranging from ions to 
proteins22–25 can be trapped. In addition, CDs exhibit low toxic-
ity and low immunogenicity,26 and they have been used in the 
pharmaceutical field by promoting CD-drug complexes in order 
to improve the absorption, distribution, metabolism, excretion, 
and toxicity (ADMET)-related properties of a drug (eg, solubil-
ity, stability, delivery and release, membrane permeability and 
absorption, toxicity). Currently, more than 30 products can be 
found in the market based on CD complexes.27–38
The determination of the interaction parameters of CDs 
and the guest compounds is essential to understand the 
molecular process of the complex formation. The informa-
tion derived from that analysis will allow preparation of the 
most suitable complex to be used with each particular drug 
in a particular application. Isothermal titration calorimetry 
(ITC) provides direct thermodynamic information on inter-
molecular binding interactions. From ITC, the equilibrium 
association constant (K
a
) and the binding enthalpy (∆H) can 
be directly and simultaneously determined, from which the 
Gibbs free energy (∆G) and the entropy (∆S) of the interac-
tion can be estimated.39–42
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In this work we have evaluated the antiviral activity of 
three compounds, identified using experimental molecular 
screening and inhibiting NS3 protease in vitro, but exhibiting 
poor inhibition activity on viral replication in cellular assays. 
We provide strong evidence for CD-dependent cellular 
internalization and delivery as an appropriate strategy to 
improve or even rescue the anti-hepatitis C virus (anti-HCV) 
potency of NS3 protease inhibitors with limited activity in 
cell-based assays, which would be otherwise discarded as 
failed lead compounds.
Materials and methods
chemical library
A collection of 1,200 compounds, supplied dissolved in 
dimethyl sulfoxide (DMSO) 100% at a concentration of 
4 mM, was commercially available (Prestwick Chemical, 
Illkirch-Graffenstaden, France). According to the manufac-
turer, the compounds are US Food and Drug Administration 
(FDA)-approved drugs selected for their high chemical and 
pharmacological diversity. In addition, information on their 
bioavailability, as well as toxicity and safety, in humans is 
available.
Ns3 protease
The N-terminal domain from full-length NS3 protein cor-
responding to NS3 protease was expressed and purified 
as described elsewhere.13,14 The isolated protease domain 
exhibits similar properties (enzymatic activity, inhibition 
constants, and allosteric activation mechanism) to those of 
the full-length protein.43
Identification of NS3 protease inhibitors
A screening procedure based on targeting a non-native 
inactive partially-folded conformation of the NS3 protease 
populated in the absence of Zn+2 was implemented. Although 
this conformational state is highly unstructured, it maintains a 
significant amount of residual structure and may be stabilized 
by ligands. Ligands binding to and stabilizing this inactive 
conformation will act as allosteric inhibitors trapping the 
NS3 protease into that inactive conformation. The molecu-
lar target, the Zn+2-free non-native inactive partially-folded 
conformation of the NS3 protease, is physiologically relevant 
given that intracellular zinc is tightly regulated at rather low 
concentration and the viral polyprotein has limited access to 
zinc as it is synthesized at the ribosome.
Ligands for NS3 protease have been identified by an 
experimental screening procedure based on a thermal-shift 
assay similar to that employed previously for identifying 
small-molecule compounds acting as Helicobacter 
pylori flavodoxin inhibitors and human phenylalanine 
hydroxylase chaperones.44,45 Ligands targeting the inactive 
partially-folded NS3 protease state have been identified 
as those compounds inducing a stabilizing effect on NS3 
protease against thermal denaturation in the absence of 
Zn+2.35 Ligand-induced NS3 stabilization was assessed by 
monitoring the thermal denaturation of recombinant pure 
NS3 protease in a FluoDia T70 High Temperature Fluo-
rescence Microplate Reader (Photon Technology Interna-
tional, Stanmore, UK). Protein-ligand solutions (100 µL) 
were dispensed into 96-well microplates (ThermoFast 96 
skirted plates; Thermo Fisher Scientific, Waltham, MA, 
USA) and overlaid with 20 µL mineral oil to prevent evapo-
ration. Protein solutions contained 2 µM NS3 protease in 
100 mM sodium acetate, 2 mM ethylenediaminetetraacetic 
acid (EDTA), pH 5, and 100 µM 8-anilinonaphthalene-1-
sulfonic acid (ANS). Ligands dissolved in DMSO were 
added at 100 µM (with a final 2.5% residual concentration 
of DMSO) to microplates containing the protein solutions 
and incubated at 25°C for 30 minutes before loading into 
the microplate reader. Control experiments with NS3 
protease samples with/without DMSO and/or Zn+2 were 
routinely performed in each microplate. Thermal dena-
turation was monitored by following the increase in ANS 
fluorescence intensity associated with protein unfolding 
(λ
exc
 = 395 and λ
em
 = 500 nm) where λ
exc
 is the excitation 
wavelength and λ
em
 is the emission wavelength. Unfolding 
curves were registered from 25°C to 75°C in 1°C steps. The 
system was allowed to equilibrate at each temperature for 
1 minute before each fluorescence acquisition. In practice, 
this represents an operational heating rate of 0.25°C/min 
approximately.
Although in the absence of Zn+2 NS3 retains some 
structure, it shows very low stability against thermal 
denaturation.23 Approximately 40% of the molecules are 
completely unfolded at 25°C. Therefore, the native base-
line in the pre-unfolding region is absent in the thermal 
denaturation assays. The mid-transition temperature can be 
operationally defined as the temperature for maximal slope 
in the unfolding curve or, alternatively, the temperature at 
which half of the maximal change in the signal is achieved. 
The absence of the native pre-unfolding baseline makes 
somewhat difficult the evaluation of the mid-transition tem-
perature following the second criterion. Therefore, hits were 
identified as those compounds shifting the temperature for 
maximal slope toward higher temperatures, compared to the 
internal controls in each microplate.
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NS3 protease activity is dependent on its interaction 
with NS4A accessory viral protein. In vitro biochemical 
studies are usually conducted in the presence of pNS4A, 
a peptide mimicking the action of NS4A. However, because 
the molecular target is the Zn+2-free partially unfolded con-
formational state of the enzyme, not able to bind NS4A, 
pNS4A was not considered.
The selected compounds were further tested: direct 
interaction with NS3 protease by titration calorimetry and 
enzymatic inhibition assays, antiviral potency in cell-based 
HCV replicon assays, and cytotoxicity in cell-based assays. 
Three compounds (compounds 1, 2 and 3) were further 
selected because they showed low (1 and 2) or negligible 
(3) antiviral potency in cell-based assays, while exhibiting 
significant in vitro inhibition effect.
ITc assay
Binding of compounds 1–3 to NS3 protease and γ-cyclodextrin 
(γ-CD) was determined with a high-sensitivity isothermal 
titration VP-ITC microcalorimeter (MicroCal, Malvern, 
Worcestershire, UK). Experiments with NS3 protease were 
performed at 25°C in 100 mM sodium acetate, 2 mM EDTA, 
pH 5. NS3 protease 20 µM solution in the calorimetric cell 
was titrated with 300 µM compound solution. Control experi-
ments were performed under the same experimental condi-
tions. Experiments with γ-CD were performed at 25°C in 
100 mM phosphate-buffered saline (PBS), pH 7. Compound 
solution (120 µM) in the calorimetric cell was titrated with 
γ-CD 1.8 mM solution. Control experiments were performed 
under the same experimental conditions.
The heat evolved after each ligand injection was obtained 
from the integral of the calorimetric signal. The heat due to 
the binding reaction was obtained as the difference between 
the reaction heat and the corresponding heat of dilution, the 
latter estimated as a constant heat throughout the experiment, 
and included as an adjustable parameter in the analysis. 
The K
a
 and the ∆H were obtained through non-linear regres-
sion of experimental data to a model considering one class 
of ligand binding sites. Data were analyzed using software 
developed in our laboratory implemented in Origin 7 (Origin-
Lab, Northampton, MA, USA).
In vitro enzymatic inhibition assay
The inhibition effect of the selected compounds on 
NS3 protease was assessed employing the fluorescence 
resonance energy transfer (FRET) substrate Ac-Asp-Glu-
Asp(EDANS)-Glu-Glu-Abu-L-lactoyl-Ser-Lys(DABCYL)-
NH
2
 (Bachem AG, Bubendorf, Switzerland).44–46 A solution 
of purified NS3 protease at 1 µM final concentration (buf-
fer sodium acetate pH 5) was treated sequentially adding: 
1) EDTA at 100 µM final concentration; 2) compound at 
0 or 25 µM final concentration (compound stock solutions are 
10 mM in 100% DMSO; therefore, the same volume of DMSO 
was added to the control samples without compounds); 3) Zn+2 
at either 200, 100, or 50 µM final concentration. Each addi-
tion of EDTA, compound and Zn+2 was followed by 30-min-
ute incubation at room temperature. Finally, substrate was 
added at 4 µM final concentration for initiating the hydrolysis 
reaction. Fluorescence intensity was measured in triplicate 
using a Synergy HT Multimode Reader (BioTek Instru-
ments Inc., Winooski, VT, USA) using 380 nm and 500 nm 
for excitation and emission wavelengths, respectively. NS3 
protease activity was determined as the initial slope of the 
curve. The quotient between the activity in the presence 
(25 µM) and the absence of a given compound provides the 
percentage of inhibition.
Preparation of γ-cD/compound 
complexes
Selected compounds were incubated 24 hours at room 
temperature with continuous stirring in a tube roller mixer. 
Different concentrations of γ-CD (from Carbosynth Com-
pany, Berkshire, UK) were added (50, 100, and 200 mM) to 
a fixed concentration of 20 mM compound in PBS (ie, 1:2.5, 
1:5, and 1:10 molar ratios) and the complex formation was fol-
lowed by spectroscopy. Main absorbance peak wavelengths 
for compounds 1–3 were shifted toward higher values after 
24 hours as an indication of complexation process. The con-
centration of compound bound to γ-CD was determined using 
the K
a
 obtained by ITC. Serial dilutions of the complexes from 
the stock solutions were prepared to final concentrations of 
120, 60, 30, 15, 7.5, 3.75 and 1.85 µM for activity and toxic-
ity assays in cell cultures.
Docking prediction
Binding pose predictions for the γ-CD/compound complexes 
were performed by computational docking using CycloPre-
dict, available online at the website http://interactions.cyclo-
dextrin.net/web. Compound information was extracted from 
PubChem database. Dreiding force field was used for energy 
minimization using built-in Chemaxon tools. PM6 semi-
empirical charges calculated by MOPAC2007 from James JP 
Stewart were added to the ligand atoms. Non-polar hydrogen 
atoms were merged, and rotatable bonds were defined. Dock-
ing calculations were carried out on beta-cyclodextrin (BCD) 
model. Essential hydrogen atoms, Kollman united atom type 
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charges, and solvation parameters were added with the aid 
of AutoDock tools.47 Affinity (grid) maps of 20×20×20 Å 
grid points and 0.375 Å spacing were generated using the 
Autogrid program.47 AutoDock parameter set- and distance-
dependent dielectric functions were used in the calculation of 
the van der Waals and the electrostatic terms, respectively. 
Docking simulations were performed using the Lamarckian 
genetic algorithm and the Solis and Wets local search 
method.48 Initial position, orientation, and torsions of the 
ligand molecules were set randomly. Each docking experi-
ment was derived from ten different runs that were set to 
terminate after a maximum of 250,000 energy evaluations. 
The population size was set to 150. During the search, a 
translational step of 0.2 Å, and quaternion and torsion steps 
of five were applied.
cells and replicon system
The highly permissive cell clone Huh 7-Lunet, as well as 
Huh 7 cells containing subgenomic HCV replicons I389luc-
ubi-neo/NS3-3′/5.1 (Huh 5-2), I377NS3-3′/wt (Huh 9-13) or 
I389/hygro-ubi-NS3-3/5.1 (a kind gift from Dr V Lohmann 
and Dr R Bartenschlager) have been described recently.49–52 
Cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Thermo Fisher Scientific) supplemented with 
10% heat-inactivated fetal bovine serum (PAN-Biotech 
GmbH, Aidenbach, Germany), 1× non-essential amino acids 
(Thermo Fisher Scientific), 100 IU/mL penicillin (Thermo 
Fisher Scientific), 100 µg/mL streptomycin (Thermo Fisher 
Scientific), and 250 µg/mL Geneticin (G418; Thermo Fisher 
Scientific).
antiviral assay with huh 5-2 cells
Antiviral assays for assessing the activity of the selected 
compounds were performed as described in literature.49–53 
Briefly, Huh 5-2 cells were seeded at a density of 5⋅103 cells 
per well in a tissue culture-treated white 96-well view plate 
(Techno Plastic Products AG, Trasadingen,  Switzerland) 
in complete DMEM supplemented with 250 µg/mL G418. 
After incubation for 24 hours at 37°C medium was removed 
and two-fold serial dilutions in complete DMEM (without 
G418) of the test compounds were added in a total volume 
of 100 µL. After 3 days of incubation at 37°C cell culture 
medium was removed and luciferase activity was determined 
using the Bright-Glo™ Luciferase Assay System (Promega 
Corporation, Fitchburg, WI, USA). The luciferase signal was 
measured using a Synergy HT Multimode Reader (BioTek 
Instruments Inc.). The EC50 was defined as the concentration 
of compound that reduced the luciferase signal by 50%.
cytostatic assay
Cytostatic assays for assessing the cell viability of the 
selected compounds were performed as described in 
literature.49–54 Briefly, Huh 5-2 cells were seeded at a density 
of 5⋅103 cells per well in a 96-well plate in complete DMEM 
with the appropriate concentrations of G418. Serial dilutions 
of the test compounds in complete DMEM (without G418) 
were added 24 hours after seeding. Cells were allowed to 
proliferate for 3 days at 37°C, after which the cell number was 
determined by CellTiter 96 AQ
ueous
 One Solution Cell Pro-
liferation Assay (Promega Corporation). The 50% cytostatic 
concentration was defined as the concentration that inhibited 
the proliferation of exponentially growing cells by 50%.
Results
Identification of NS3 protease ligands 
by experimental screening
Lead compounds were identified as those compounds shifting 
the temperature for maximal slope to higher temperatures, 
compared to the internal controls (Figure 1). The extent of 
the stabilization effect against thermal denaturation does not 
necessarily correlate with the binding affinity of the different 
compounds, as discussed below. Therefore, the increase stabil-
ity is a valid index for selecting hits, but not a valid index for 
establishing an affinity ranking. Compounds 1–3 were selected 
from this screening procedure (Figure 2) for further charac-
terization. The selected compounds do not show high affinity; 
their moderate affinity toward the molecular target is typical 
from primary hits that must progress through optimization.
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?
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Figure 1 experimental screening for ligands binding to the Zn+2-free Ns3 protease.
Notes: Thermal denaturation curves of Zn+2-free Ns3 protease followed by aNs 
fluorescence in the presence of different compounds (100 mM sodium acetate, pH 
5, 2 mM eDTa). Free protein with no compound (line with error bars), compound 1 
(dash-dotted line), compound 2 (dotted line), and compound 3 (solid line) are 
shown.
Abbreviations: eDTa, ethylenediaminetetraacetic acid; au, arbitrary units; aNs, 
8-anilinonaphthalene-1-sulfonic acid.
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Binding of selected compounds to Ns3 
protease by ITc
The dissociation constants (K
d
) for the interaction between 
NS3 protease with the selected compounds 1–3 were 
determined by ITC (Table 1). The K
d
 for these compounds 
are in the micromolar range. The binding affinity of these 
compounds is moderate, but it is important to point out that 
these are lead compounds obtained directly from molecular 
screening, with no further optimization.
Inhibition of Ns3 protease in vitro 
by selected compounds
Direct inhibition of NS3 protease was tested with the selected 
compounds. The protocol is based on the Zn+2-free non-native 
inactive partially-folded conformation of the NS3 protease, 
a physiologically relevant conformation given that intracel-
lular zinc is tightly regulated at rather low concentration 
and the viral polyprotein has limited access to zinc as it is 
synthesized at the ribosome. Selected compounds will bind 
and stabilize that inactive alternative conformational state 
acting as allosteric inhibitors. However, because Zn+2 and 
these compounds bind to different conformational states of 
the enzyme, they behave as competitive ligands according 
to a standard Michaelis-Menten mechanism.
The protocol consisted of: 1) removing Zn+2 from the 
enzyme by adding EDTA (to obtain Zn+2-free NS3 pro-
tease); 2) adding compound (to the Zn+2-free NS3 protease); 
3) adding Zn+2 to the enzyme; 4) and initiating the catalytic 
reaction by adding the substrate. According to the K
d
 for the 
EDTA-Zn+2 at pH 5 (K
d
 of 0.8 nM),11 and the total concen-
trations of Zn+2 (50, 100 and 200 µM) and EDTA (100 µM) 
employed in the inhibition assay, the concentration of free 
Zn+2 for each case is 0.8 nM, 0.9 µM, and 0.1 mM, covering 
five orders of magnitude.
Figure 3 shows the reduction in NS3 protease activity 
in the presence of the selected compounds. Zn+2 concentra-
tion modulates the extent of the inhibitory effect: at typical 
intracellular Zn+2 concentrations (in the low nanomolar range 
or below) the inhibition of the enzyme is much larger than at 
higher concentration of Zn+2. This was expected, since zinc 
promotes proper folding of the enzyme.
Binding of selected compounds to γ-cD
The thermodynamic parameters of γ-CD interaction with the 
selected compounds have been determined by ITC (Table 2) 
allowing the determination of the amount of compound (1–3) 
complexed to γ-CD by applying chemical equilibrium and 
mass conservation equations. In order to visually describe 
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Figure 2 compounds selected from experimental screening and exhibiting antiviral activity in cell assays.
Notes: chemical structures of the selected compounds by experimental screening were further tested in cell-based, calorimetric and enzymatic assays.
Table 1 Interaction of Ns3 protease with selected compounds
Kd (µM)
compound 1 6.3±0.9
compound 2 11±2
compound 3 7±1
Notes: Dissociation constants obtained by ITc (25°c, 100 mM sodium acetate, 2 mM 
eDTa, ph 5). Data are mean ± standard deviation.
Abbreviations: Kd, dissociation constant; ITc, isothermal titration calorimetry; 
eDTa, ethylenediaminetetraacetic acid.
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Figure 3 In vitro enzymatic inhibition of Ns3 protease.
Notes: Ns3 protease activity was determined as the initial slope of the curves. 
The percentage of activity is calculated as the quotient between the activity of 
Ns3 protease in the presence (25 µM) and the absence of a given compound 
(compound 1, closed triangles; compound 2, closed circles; compound 3, closed 
squares). experiments were carried out in triplicate and the relative errors were 
12%. Physiological Zn+2 concentration lies in the nanomolar-to-picomolar region, 
where the competitive effect of Zn+2 is greatly diminished. V0, initial velocity 
of hydrolysis reaction catalyzed by Ns3 protease in the presence of inhibitor at 
concentration [I].
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the interaction, an algorithm has been applied (from 
MOPAC2007 computer program) and a possible interaction 
pose can be visualized (Figure 4). Prediction results from 
computational docking in terms of interaction energy are in 
agreement with the experimental results (Table 2).
antiviral activity of selected compounds 
and γ-cD complexes in hcV 
sub-genomic replicon cells
Our novel screening method is based on the identification of 
compounds that act as allosteric inhibitors by interacting with 
the inactive partially-folded Zn+2-free NS3 protease confor-
mation. The next logical step consisted of testing their potency 
in inhibiting viral replication in cell-based assays. In vitro 
HCV replication assays were performed with genotype 1b 
Con1 HCV sub-genomic replicon (Huh 5-2 cells). Viral 
replication levels can be easily monitored by quantifying 
the reporter (luciferase).
Despite their interaction with the protease with a K
d
 of 
10 µM (Table 1), the selected compounds exhibited poor 
EC50 values in cell culture: 25, 40, and .120 µM for com-
pound 1, compound 2, and compound 3 respectively (Table 3). 
Compounds 1 and 2 probably would be discarded from fur-
ther consideration based on the low activity in cell assays, and 
compound 3 would be considered as a false positive (EC50 
could not even be determined at the experimental conditions), 
if the primary screening has not been previously performed 
(Table 3). The antiviral activity of the three compounds 
was determined, either as a free species or in complex with 
γ-CD, in order to test the improvement brought about by the 
protecting role of the molecular carrier.
All three γ-CD complexes inhibited HCV replicon 
replication in a dose-dependent manner with EC50 lower 
than 100 µM (Figure 5A and Table 3). The anti-HCV activ-
ity was not the result of a cytostatic effect, since the 50% 
cytostatic concentration values for these compounds were 
significantly higher than the EC50 values. In addition, a cor-
relation can be observed between the percentage of the viral 
replication inhibition and the concentration of the γ-CD used 
(Figure 5B), indicating a dose-dependent specific effect from 
the molecular carrier interacting with each compound and 
providing a suitable vehicle for internalization and intracel-
lular delivery. All experiments included appropriate control 
tests with compound-free γ-CD, where the luminescence and 
viability data remained at 100% (data not shown). Therefore, 
the observed effect for the γ-CD-compound complexes is due 
to the presence of the compounds.
Discussion
Primary and secondary screenings are designed and imple-
mented on the basis of different biological complexity 
levels (molecular target, cell, organism), different reporter 
Figure 4 Docking of compound/γ-cD complexes.
Notes: (A) compound 1; (B) compound 2; (C) compound 3. γ-cD: blue ball and stick; compounds: ball functional groups representation.
Abbreviation: γ-cD, γ-cyclodextrin.
Table 2 Interaction of γ-cD with selected compounds
ITC CycloPredict Docking
Ka (M
-1) Kd (µM) ∆G (kcal/mol) ∆H (kcal/mol) -T∆S (kcal/mol) ∆G (kcal/mol)
compound 1 6,300±1,000 160±30 -5.2±0.1 -3.2±0.3 -2.0±0.3 -4.15±0.08
compound 2 5,500±1,000 180±40 -5.1±0.1 0.5±0.3 -5.6±0.3 -4.64±0.09
compound 3 3,900±800 260±50 -4.9±0.1 -0.7±0.3 -4.2±0.3 -3.05±0.06
Notes: Thermodynamic parameters obtained by ITc (25°c in 100 mM PBs, ph 7) and cycloPredict Docking algorithm. Data are mean ± standard deviation.
Abbreviations: γ-cD, γ-cyclodextrin; Kd, dissociation constant; Ka, association constant; ITc, isothermal titration calorimetry; PBs, phosphate-buffered saline; ∆g, gibbs 
free energy; ∆h, binding enthalpy; –T∆s, entropic contribution.
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probes, and under different experimental conditions. 
Selected compounds from primary screenings are directed 
to further optimization (eg, biophysical characterization, 
designing of functional derivatives) and parallel cell-based 
secondary screenings, where, in case their performance is 
poor, they may either be rejected as compounds exhibiting 
insufficient activity or be considered as false positives. 
Taking into consideration the primary screening data, 
together with further pieces of evidence from a biophysi-
cal characterization of the selected compounds with the 
molecular target, it is possible to devise strategies for 
rescuing the activity of lead compounds in cell-based 
secondary screenings.
In this work we present three compounds identified from 
a primary screening as inhibitors of the hepatitis C NS3 
protease. Despite substantive evidence for a direct interac-
tion with the target, they show low or negligible activity in 
cell-based viral replication assays. A strategy based on γ-CD 
as a molecular carrier (potentially beneficial for storing, 
transporting, protecting, and delivering the compounds) 
has been employed for rescuing their activity for further 
optimization.
The thermal-shift assay is a fast and easy methodology 
for identifying compounds binding to a given protein tar-
get. However, there are some important caveats that must 
be stressed. The extent of the stabilizing effect of a ligand 
on a given protein (ie, increase in the mid-transition tem-
perature) not only depends on the binding affinity and the 
concentration of compound, but also on the ∆H and, to a 
lesser extent, the binding heat capacity. For example, two 
compounds binding with similar affinities will promote 
mid-transition temperature increases very differently if 
their binding enthalpies are very different. Similarly, com-
pounds binding with very different affinities may promote 
similar mid-transition temperature increases if their bind-
ing enthalpies are very different. In addition, compounds 
binding to both the folded and the unfolded states of the 
protein with similar binding affinities may induce little or 
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Figure 5 Inhibition of hcV replicon in cell assays.
Notes: (A) evaluation of activity and cytotoxicity of the selected compounds in cell assays. hcV replicon replication rates (solid lines and solid symbols) and cell survival curves 
(dash lines and open symbols) are shown for: γ-cD-free compound 3 (squares), compound 3:γ-cD 1:2.5 complex (circles); compound 3:γ-cD 1:5 complex (triangles); compound 
3:γ-cD 1:10 complex (diamonds). (B) Viral replication inhibition level as a function of γ-cD concentration (maximal loss in luminescence percentage observed in [A]).
Abbreviations: γ-cD, γ-cyclodextrin; hcV, hepatitis c virus; UTc, untreated controls.
Table 3 antiviral potency and cytotoxicity of selected compounds
γ-CD (molar ratio) Compound 1 Compound 2 Compound 3
EC50 (µM) CC50 (µM) EC50 (µM) CC50 (µM) EC50 (µM) CC50 (µM)
0 25±4 .120±20 40±6 .120±20 .120±20 .120±20
1:2.5 12±2 .120±20 5.0±0.8 90±10 .100±20 .120±20
1:5 9±1 .120±20 2.5±0.4 40±6 15±2 .120±20
1:10 6.0±0.9 .120±20 2.5±0.4 40±6 5.0±0.7 .120±20
Notes: estimated values of ec50 (50% effective concentration) and cc50 (cytotoxic concentration 50%) for the selected compounds in cell assays. Data are mean ± standard 
deviation.
Abbreviation: γ-cD, γ-cyclodextrin.
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no stabilization at all (leading to false negatives). Therefore, 
the extent of the mid-transition temperature increase in 
thermal shift assays is not valid for establishing an affin-
ity ranking for the ligands, but just a criterion for selecting 
ligands binding to the protein target. Additional biophysical 
(eg, calorimetry, spectroscopy) or enzymatic assays are 
always further required for providing more direct information 
on the protein-ligand interaction.
Using this screening method, three compounds were 
identified. They were able to bind to the inactive protease 
and increase its stability (Figures 1 and 2), and their K
d
 for 
the interaction with NS3 protease, as determined by ITC, 
were in the µM range (Table 1). In addition, they could also 
inhibit the NS3 protease activity in vitro (Figure 3). Addi-
tional assays with human pancreatic α-chymotrypsin showed 
a small or negligible inhibition effect (results not shown), 
indicating they are specific for NS3 protease. However, when 
their antiviral activity in cell culture was evaluated, dimin-
ished HCV replicon inhibition was observed; in particular, 
compound 3 showed no antiviral effect when administered 
free (Figure 5), and compounds 1 and 2 showed significantly 
reduced antiviral potency (Table 3).
It is interesting to point out that, overall, the primary 
screening hit rate was 1.25% (15 positive hits from a col-
lection of 1,200 compounds), and all 15 hits (100%) exhib-
ited significant inhibition activity against NS3 protease. 
However, less than 50% of the compounds (seven out of 15) 
showed significant antiviral activity in cell assays (EC50 
lower than 50 µM).
The discrepancy between the activity assays and the cell-
based assays could be explained considering an insufficient 
cellular internalization for the three compounds, leading to 
an insufficient intracellular concentration for HCV replicon 
inhibition. In order to overcome this difficulty and recover 
the antiviral activity of these compounds, we exploited the 
possibility of using CDs as compound carriers for cellular 
uptake and distribution.
We studied the interaction of these three compounds 
with three types of CDs (α-, β-, and γ-CD) by ITC. γ-CD 
was finally chosen for its higher affinity in all cases, with 
K
a
 very similar for the three compounds (K
a
 from 4,000 
to 6,000 M-1). In the case of compound 1, the interaction 
seemed to be more specific because the enthalpic contribu-
tion to the binding Gibbs energy was larger than the entropic 
one. And for compound 3, the situation was reversed, with 
a larger entropic contribution. For drug administration and 
delivery a substantial affinity of γ-CD for the compound in 
the extracellular environment coupled to a fast release in the 
intracellular medium would be desirable.
In order to substantiate the ITC binding data, we per-
formed a computational simulation of the interaction using 
a specific tool for CD docking, and the results obtained were 
consistent with those determined experimentally (Figure 4). 
In compound 1, two aromatic rings are twisted through its 
linker and the interaction with γ-CD covers both sides of its 
internal cavity; this compound was the one that exhibited 
the greatest enthalpy term and, probably, the most specific 
binding. In the case of compound 2, with three rings without 
linker, the interaction occurs in the same side of the γ-CD 
cavity. In compound 3, the interaction also covers both sides 
of the γ-CD cavity (as in compound 1), but the presence of 
only one aromatic ring could reduce the strength and specific-
ity of binding, which is in agreement with the experimental 
thermodynamic data.
In all three compounds their complexation with γ-CD 
increased their potency as antivirals in cell-based assays, 
compared to the free compounds. Compound 1 showed a five-
fold activity increase, and its cytotoxic effect in cells did not 
change. Compound 2 showed a 16-fold activity increase, but 
its cytotoxicity effect was also increased (at least three-fold). 
Compound 3 constitutes the most successful improvement, 
since the free compound exhibited no antiviral effect at all 
and its complex with γ-CD shows an EC50 value of 5 µM, 
with no increase in cell cytotoxicity. In addition, the effect 
of γ-CD is dependent on the γ-CD:compound molar ratio, 
indicating a specific effect derived from the formation of 
the complexes.
We have been able to enhance the antiviral potency of 
in vitro selected compounds by complexation with γ-CD 
(in the case of compounds 1 and 2). More importantly, the 
antiviral activity in compound 3 was completely recovered. 
It is important to point out that compound 3 would have 
been discarded if only a cell-based inhibition assay had been 
carried out. Therefore, a combination of activity and cell-
based assays provide invaluable information for screening 
and selecting lead compounds for further optimization. For 
a compound that interacts and inhibits the protein target, but 
shows no antiviral potency in cellular assays, insufficient 
cellular internalization or substantial efflux transport would 
be two plausible causes for that outcome. Chemical modifica-
tion of the compound for improving cellular uptake or mini-
mizing efflux transport, yet maintaining antiviral potency, 
would be a possible strategy for overcoming that problem. 
Alternatively, the use of carrier molecules facilitating the 
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cellular internalization and evading the efflux machinery 
constitutes an alternative advantageous approach, because 
no chemical modification in the compound is required. 
We have provided evidence for the improvement in the 
antiviral activity of three compounds in cell culture by using 
γ-CD as a carrier molecule. Therefore, if compound vehicu-
lization studies are performed in parallel with compound 
screening and optimization procedures, it will be possible 
to decrease the concentration of a given compound required 
for obtaining a certain pharmacological effect within the 
cell (dose reduction), and to recover the activity of those 
compounds that could have been initially discarded because 
of their low (or even lack of) potency in cell assays, thus 
reducing false negatives.
The specific features of the interaction of the carrier 
molecule with a given cargo (eg, binding affinity, interaction 
enthalpy and entropy, kinetic association and dissociation rate 
constants) will be key factors for designing and optimizing an 
efficient molecular delivery system, and for that purpose we 
are currently performing a thorough study with a collection 
of antiviral compounds targeting the NS3 protease.
Conclusion
Compounds exhibiting in vitro bioactivity may show reduced 
activity in cell culture assays because of insufficient cellular 
internalization or significant cellular efflux. The employment 
of carrier/delivery molecules represents a potential strategy 
for recovering those compounds for further optimization. 
We have proven successful this approach for three inhibitors 
targeting the NS3 protease from the HCV by complexation 
with γ-CD. Thus, it is possible not only to decrease the 
concentration of a given compound required for obtaining 
a certain pharmacological effect within the cell (reduction 
of dose with the added benefit of reducing potential side-
effects), but also to recover the activity of those compounds 
that could have been initially discarded because of their 
low (or even lack of) potency in cell assays, thus reducing 
false negatives. Future work will involve: 1) optimization of 
binding affinity and toxicity of the compounds; 2) character-
ization of the activity profile regarding different viral repli-
cons and the emergence of resistance-associated mutations; 
3) assessment of alternative carrier molecules; 4) optimiza-
tion of the compound/carrier molar ratio; 5) evaluation of in 
vivo efficacy in animal models.
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